Redhill Biopharma
RDHL
41 hedge funds and large institutions have $46.6M invested in Redhill Biopharma in 2020 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
65% more capital invested
Capital invested by funds: $28.1M → $46.6M (+$18.4M)
39% more call options, than puts
Call options by funds: $981K | Put options by funds: $705K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
11% less funds holding
Funds holding: 46 → 41 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$2.85M |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$2.51M |
| 3 |
GS
Gagnon Securities
New York
|
+$764K |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$344K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
+$303K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$565K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$423K |
| 3 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$289K |
| 4 |
CAM
Claret Asset Management
Montreal,
Quebec, Canada
|
-$172K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$172K |
RDHL Hedge Fund Activity: Q2 2020 in Review
41 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q2 2020, worth a combined $46.6M — up 65% from $28.1M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of RDHL and 3 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 18 added.
The largest buyer was Disciplined Growth Investors, adding an estimated $2.85M. The largest seller was State Street, cutting an estimated $565K.
- 41 institutional investors held Redhill Biopharma (RDHL) as of Q2 2020, down from 46 in Q1 2020.
- Funds reported $46.6M of Redhill Biopharma stock for Q2 2020, up 65% quarter-over-quarter.
- 3 funds opened new Redhill Biopharma positions in Q2 2020 and 8 closed out, a net change of -5 holders.
- The largest Redhill Biopharma buyer in Q2 2020 was Disciplined Growth Investors, an estimated $2.85M added.
- The largest Redhill Biopharma seller in Q2 2020 was State Street, an estimated $565K sold.
Based on aggregated 13F filings for Q2 2020.